ArticleEuropean journal of medical research2025
Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesMost of the myelodysplastic syndromes (MDS) patients suffer from iron overload (IOL) due to ineffective hematopoiesis and repeated blood transfusions. IOL may affect the survival of MDS patients, but the related mechanism has not been fully clarified. We aimed to provide clinical evidence for the impact of IOL on the immunity and prognosis of MDS patients.
methodsThe clinical features and outcomes of 144 patients with MDS between March 2019 and December 2023 were analyzed. Patients were classified into the IOL group (ferritin > 1000 ng/mL) and the non-iron overload (NIOL) group (ferritin ≤ 1000 ng/mL).
resultsThe median age of the patients was 64 (22-89) years, and IOL MDS patients had a poorer performance status. IOL MDS patients had significantly higher alanine aminotransferase and blood glucose levels. White blood cell counts and hemoglobin levels were significantly lower in IOL MDS patients. Meanwhile, the proportion of erythrocyte and megakaryocyte counts were significantly decreased in MDS patients with IOL. The incidence of 7q- chromosome abnormalities in IOL group was significantly higher. The level of Interleukin-6 was markedly elevated in patients with IOL MDS, accompanied by significant abnormalities in dendritic cells. Survival analysis indicated that IOL MDS patients had a shorter survival duration. Age ≥ 60 years, ferritin > 1000 ng/mL, complex chromosomal abnormalities, and gene mutations in TP53 and RUNX1 were independent adverse prognostic factors for MDS patients.
conclusionsIOL MDS patients exhibit poorer performance status and organ function, with hematopoietic and immune function abnormalities potentially affecting their survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.